All In Biotech

Drug Trial Radar · NCT06945406

A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

124

Planned (sponsor's estimate)

Start

May 16, 2025

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Apr 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate how well LY4057996 is tolerated and what side effects may occur in healthy participants and participants with Type 1 and Type 2 Diabetes. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4057996 gets into the bloodstream and how long it takes the body to eliminate it. The study will last 11 weeks for Part A1-A2, 4 weeks for A3-A5, 6 weeks for Part B and 7 weeks for Part C, all approximations, excluding a screening period.

Conditions

  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2

Interventions

  • LY4057996 SCDrug

    Administered SC

  • LY4057996 IVDrug

    Administered IV

  • Placebo SCDrug

    Administered SC

  • Placebo IVDrug

    Administered IV

  • Degludec SCDrug

    Administered SC

  • Lispro SCDrug

    Administered SC

  • Degludec IVDrug

    Administered IV

  • Pre-study basal insulin SCDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline to Study Completion (Up to 47 Weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Profil Institut für Stoffwechselforschung

    Neuss, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.